Axiom MRC has updated all it's market research reports with the Economic Impact Analysis of COVID19 Pandemic on the market. Our team of analyst are following Comprehensive Three Dimensional (3D) Research Methodology along with large number primary interviews with key industry participants to bring insightful market reports to meet the current market requirements.
A contract development and manufacturing company (CDMO) is a firm that provides drug development and manufacturing services to the pharmaceutical sector. For various research phases, CDMOs and pharmaceutical firms ideally collaborate to outsource medication development and manufacture. A contract manufacturing organisation (CMO) often provides entire services to the pharmaceutical sector, from medication discovery to manufacture. Besides, in pharmaceutical industry, the clients can extend their technical resources by outsourcing to a CMO without incurring additional costs. The market helps to focusing core competencies and high-value projects while lowering or eliminating infrastructure and technical staff that might help the customer to manage internal resources and expenditures. Many CDMO’s are currently delivering a services such as drug discovery, preclinical and clinical trial, API and finished product manufacturing ,dosage form development. This services covers the all value chain from drug discovery and commercialization. Additionally, pharmaceutical companies are increasingly need CMO services in order to expand pharmaceutical outsourcing. As pharmaceutical companies are looking for opportunities to strength their services offering by choosing the merge with small and large pharma and biotech firms.
As the COVID-19 epidemic spreads, the focus on the pharmaceutical industries and employees' health and safety is increasing. As the world's most mature and competitive industry, it has long reaped the benefits of several unpriced environmental and social consequences. During COVID-19 pandemic, the CMO/CDMO service sector is extremely positioned to address some of the issues that drug developers are facing. From medication development through clinical trials, supplies, production, and supply chain logistics, the pandemic has had a significant influence on the pharmaceutical and biopharmaceutical industries. However, due to worldwide stockpiles of medicines and APIs, drug shortages caused by COVID-19 are projected to be limited in the immediate term. Supply from Chinese industrial facilities has been severely decreased since the lockdowns were implemented.
The global pharmaceutical CDMO market is analysed based on service type, research phase and geography.
By service, pharmaceutical CDMO market is segmented into the active pharmaceutical ingredient (API) manufacturing, finished dosage formulation (FDF) development and manufacturing, secondary packaging. Finished dosage formulation (FDF) is sub segmented into the solid dose formulation, liquid dose formulation and injectable dose formulation. Active pharmaceutical ingredient (API) segment is dominating the Pharmaceutical CDMO Market. As the Growing number of biologics API in the pipeline stage and growing adoption of API biologics into multitude of therapies is the important factor for the growth of Active Pharmaceutical Ingredient (API) Manufacturing. Implementation of patient centric by many pharmaceutical contract manufacturing company has become crucial factor in improving patient adherence by providing dose manufacturing features in packing.
By research phase, pharmaceutical CDMO market is segmented into Pre-clinical, Phase I, Phase II, Phase III and Phase IV. The Pre-clinical followed by Phase I, among others are likely to witness increasing demand for market. Increasing collaboration among pharmaceutical companies and increasing research and development for outsourcing of clinical trial are increasing the demand for clinical trial services. The increasing collaboration among CDMO to provide innovative packaging solution are the impactive factors for the clinical trial. CDMO require R& D for the innovative drug development this factor are likely increase the demand for clinical trial phases.
In terms of geography, the pharmaceutical CDMO Market is studied for the key regions including North America, Europe, Asia Pacific, and Rest of the World. North America is anticipated to gain major market in global pharmaceutical CDMO market. The presence of countries like United States, Canada and Mexico has been the largest contributor to North America region growth in the global CDMO market in terms of geographical areas, owing to rising partnerships and the vast range of services supplied by CDMOs. Due to its highly qualified workforce and low research and development costs. On the other hand, Asia Pacific is the fastest-growing market for CDMO. The market in Asia pacific is expected to grow at specific growth rate during the forecast period. Because of highly skill work force and low R &D and manufacturing cost advantage offered in these region
The key competitors of this market include Catalent Inc., Recipharm AB, Jubilant Life Sciences Ltd, Patheon Inc., Boehringer Ingelheim Group, Pfizer CentreSource, Aenova Holding GmbH, Famar SA, Baxter Biopharma Solutions, Lonza Group, CMIC Holdings Co. Ltd, Covance Inc., Syneos Health Inc., LSK Global Pharma Service Co. Ltd, Novotech Pty Ltd, PAREXEL International Corporation, Pharmaceutical Product Development LLC, PRA Health Sciences Inc., Quanticate Ltd.
January 2021: CMIC Co Ltd. has joined the Decentralized Trials & Research Initiative (DTRA), an alliance aimed at stimulating the rapid adoption of decentralised clinical trials. CMIC would become a member of the DTRA Leadership Council, allowing it to effectively advance decentralised trials in Japan by expanding its ties to relevant organisations and firms in the United States.
December 2020: Illingworth Research Group, a well-known clinical research home health services company, has been acquired by Syneos Health. COVID-19 has accelerated the demand for in-home clinical trial services, which have seen an increase in demand in recent years as healthcare has become more localised.
October 2020 : Parexel had announced a strategic collaboration with Synairgen plc, a respiratory drug discovery and development company, to conduct a pivotal phase III study of an interferon beta (IFN-beta) treatment for patients hospitalised with COVID-19.
Global pharmaceutical CDMO Market is segmented based on service type, research phase, and geography. By service type the market is segmented into the active pharmaceutical ingredient (api) manufacturing, finished dosage formulation (FDF) development and manufacturing, secondary packaging. Finished Dosage Formulation (FDF) is sub segmented into the solid dose formulation, liquid dose formulation and injectable dose formulation. Based on research phase the market is segmented into Pre-clinical, Phase I, Phase II, Phase III and Phase IV. The Global Pharmaceutical CDMO Market is studied across various key countries of regions such as, North America, Europe, Asia Pacific and Rest of the World.
The key competitors of this market include Catalent Inc., Recipharm AB, Jubilant Life Sciences Ltd, Patheon Inc., Boehringer Ingelheim Group, Pfizer CentreSource, Aenova Holding GmbH, Famar SA, Baxter Biopharma Solutions, Lonza Group, CMIC Holdings Co. Ltd, Covance Inc., Syneos Health Inc., LSK Global Pharma Service Co. Ltd, Novotech Pty Ltd, PAREXEL International Corporation, Pharmaceutical Product Development LLC, PRA Health Sciences Inc., Quanticate Ltd.
Why to buy this report:
